ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
27 announcements
Rekvina Laboratories has scheduled its Board meeting for November 13, 2026, to approve Q2 FY27 un-audited financial results. No material financial figures are disclosed at this stage.
Subsidiary Radiant Parenterals will temporarily shut its manufacturing facility from October 28, 2026. The shutdown supports renovation and installation of an additional vial line.
Rekvina Laboratories Limited submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Rekvina Laboratories Limited has appointed Mr. Subrata Samanta as its new Chief Financial Officer and Key Managerial Personnel, effective October 7, 2026.
Rekvina Laboratories Ltd held its 38th Annual General Meeting on September 29, 2026, approving financial statements and appointing directors.
Rekvina Laboratories Ltd announced a change in its registered office within the city and the resignation of its Managing Director, Mr. Amit Shah.
Mr. Amit Mukesh Shah has resigned as Managing Director and Director of Rekvina Laboratories Limited, effective September 11, 2026.
The company filed its shareholding pattern reporting changes in share distribution following the recent open offer. The public shareholding has fallen below the minimum threshold.
Rekvina Laboratories' board meeting approved the Annual Report for FY2025-26 and the notice for the upcoming AGM. It also noted the resignation of the Company Secretary.
Rekvina Laboratories' 38th AGM will be held online on September 29, 2026. The board also approved the notice and noted the company secretary's resignation.
Mr. Deepak Khandelwal has resigned from his position as Company Secretary and Compliance Officer of Rekvina Laboratories Limited, effective from September 2, 2026.
Dhruvalkumar Patel acquired 11,12,562 equity shares (10.01% stake) in Rekvina Laboratories Ltd via open offer and preferential allotment. The acquisition increases the investor's significant holding in the company.
Rekvina Laboratories Limited clarified that recent stock price movements are market-driven and not due to any undisclosed price-sensitive information or material developments.
Rekvina Laboratories Ltd reported revenue from operations of ₹0.7 Cr and a net loss of ₹0.1 Cr for Q1 FY27.
Rekvina Laboratories allotted 50,87,750 equity shares on a preferential basis, aggregating ₹5.09 Crore, to acquire Radiant Parenterals Limited as a wholly-owned subsidiary.
Rekvina Laboratories Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending June 30, 2026. No changes in promoter control were disclosed.
Rekvina Laboratories Limited has scheduled a board meeting on August 13, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.
Acquirers Surbhit Mukesh Shah and others completed an open offer for Rekvina Laboratories Limited, acquiring 14,41,863 shares. The total consideration for the open offer shares reached ₹1.44 Crore.
Rekvina Laboratories Ltd has filed its quarterly shareholding pattern for the period ending June 30, 2026, as per regulatory requirements.
Rekvina Laboratories Ltd published a pre-offer advertisement for an open offer. Acquirers seek to acquire 100% equity shares of the company.
Rekvina Laboratories Ltd reported revenue from operations of ₹0.7 Cr and a net loss of ₹0.1 Cr for Q4 FY26.
Rekvina Laboratories reported audited financial results for the year ended March 31, 2026. The company also approved an authorized capital increase and potential acquisition.
Rekvina Laboratories scheduled a board meeting for May 21, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-announcement.
Rekvina Laboratories Limited announced the voting results of its Extra-Ordinary General Meeting held on April 10, 2026. Shareholders approved all six resolutions, including an authorized capital increase and a preferential share issue. The resolutions were passed with requisite majorities via remote e-voting and poll processes.
Rekvina Laboratories Limited held its first EGM of FY2026-27 on April 10, 2026. Shareholders considered resolutions including increasing authorized share capital, altering the Memorandum and Articles of Association, and approving preferential equity allotments for cash and non-cash consideration. The meeting concluded with 17 members present and voting conducted via polling papers.
Rekvina Laboratories Ltd informed BSE that the requirement to submit an Annual Secretarial Compliance Report for FY2026 is not applicable. The company claims exemption under Regulation 15(2) of SEBI LODR as its paid-up equity capital and net worth remain below the prescribed thresholds of ₹10 Crore and ₹25 Crore respectively.
Rekvina Laboratories Ltd submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018. For the period ended March 31, 2026, the company reported nil share certificates were received for dematerialisation. This is a routine regulatory disclosure with no material financial impact.